SCHEMBL19494286

SCHEMBL19494286

CC(=O)Nc1sc([S+]([O-])Cl)c(C)c1C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
FLT3 P36888 1/20 0.43
AIP O00170 1/20 0.41
SGTA O43765 1/20 0.41
TOMM70 O94826 1/20 0.41
STIP1 P31948 1/20 0.41
PPP5C P53041 1/20 0.41
FKBP4 Q02790 1/20 0.41
PPID Q08752 1/20 0.41
FKBP5 Q13451 1/20 0.41
FKBP8 Q14318 1/20 0.41
TOMM34 Q15785 1/20 0.41
DNAJC7 Q99615 1/20 0.41
AIPL1 Q9NZN9 1/20 0.41
STUB1 Q9UNE7 1/20 0.41
ALDH1A1 P00352 10/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246427 0.76 KMT2A (0.49) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL11324603 0.76 AIP (0.66) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL16246353 0.72 KMT2A (0.44) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL11641915 0.72 KMT2A (0.44) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL19494287 0.70 KMT2A (0.46) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL8290398 0.64 ALDH1A1 (0.77) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL16246479 0.64 ALDH1A1 (0.49) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL8277600 0.64 AIP (0.62) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL16246338 0.63 ALDH1A1 (0.48) KMT2AKDM4EMEN1CYP1A2CYP2C19
SCHEMBL1926572 0.62 MAPT (0.48) KMT2AKDM4EMEN1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2994463-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2017-10-25 EP disclosed